HIMS & HERS HEALTH INC

HIMS & HERS CFO’s 10b5‑1 buy of 14k shares at $5.01 shows insider confidence in the company’s telehealth and IT‑services growth, amid market volatility.

CEO Dudum Andrew’s July 2026 sale of 463k HIMS & HERS HEALTH shares shows strategic divestment, not loss of confidence, and signals a shift in portfolio while the company’s telehealth prospects stay strong.

HIMS & HERS HEALTH insider sale: CPO Autor offloads 16,773 shares at $27.85, a disciplined 10b‑5‑1 move that signals routine portfolio rebalancing, not distress.

Hims & Hers insider buying surge shows management’s confidence in a comeback, highlighting new AI & peptide strategies and equity‑focused incentives.

Insider CFO buys HIMS & HERS shares at $5.01, revealing confidence amid bullish sentiment and pending lawsuit.

Insider CFO buys 71k HIMS shares amid 14.8 % weekly rise—signals confidence in peptide‑therapy push despite negative earnings.

Insightful insider trading analysis shows Hims & Hers CFO buying at low prices while selling near market highs—signaling confidence in growth and a potential rebound for investors.

Insider buying shows Hims & Hers CFO confidence as he buys 12,553 shares amid volatile markets, signaling bullish outlook for telehealth growth.

CEO Dudum Andrew’s massive RSU buy in Hims & Hers, spurred by a Novo Nordisk partnership and a 64‑point social‑media surge, boosts shares 57% and signals strong growth, but valuation remains a key concern for investors.

Insider buying spikes Hims & Hers stock, signaling CEO confidence and a pivot to Novo Nordisk obesity drugs that could boost earnings and valuations.